Summary Haematology is at a crossroads, divided between haemato‐oncology and the disparate disciplines collectively known as ‘non‐malignant’ haematology. This latter term is a misnomer that devalues a spectrum of complex, life‐threatening conditions and contributes to workforce shortages and research inequities. This article argues for the formal adoption of the term Medical Haematology to redefine this domain. We chart its central role across medicine, from guiding anticoagulation, transfusion and thrombosis care across specialties to addressing global health challenges. We highlight its pioneering contributions to molecular medicine and immunotherapy, exemplified by gene therapy for haemophilia and the repurposing of chimeric antigen receptor T cells for autoimmune disease. Finally, we present a forward‐looking blueprint involving establishment of ‘Blood Teams’, revamping educational curricula and championing equity to secure the speciality's future. Embracing Medical Haematology is a strategic imperative to reflect the life‐threatening nature of many conditions within the speciality, attract trainees, rebalance research priorities and firmly re‐establish haematology's indispensable role at the heart of modern medical practice.
Toh et al. (Tue,) studied this question.